Beijing Chunlizhengda Medical Instruments Valuation
Is 1858 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 1858 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1858 (HK$8.38) is trading below our estimate of fair value (HK$13.67)
Significantly Below Fair Value: 1858 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1858?
Key metric: As 1858 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 1858's PE Ratio? | |
|---|---|
| PE Ratio | 18.8x |
| Earnings | CN¥158.35m |
| Market Cap | CN¥4.84b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.1x |
| Enterprise Value/EBITDA | 16.9x |
| PEG Ratio | 0.6x |
Price to Earnings Ratio vs Peers
How does 1858's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 21.9x | ||
2172 MicroPort NeuroScientific | 21.5x | 22.5% | HK$5.2b |
2291 LEPU ScienTech Medical Technology (Shanghai) | 27.3x | n/a | HK$6.4b |
1789 AK Medical Holdings | 29.7x | 29.1% | HK$6.0b |
3600 Modern Dental Group | 9x | 16.5% | HK$3.7b |
1858 Beijing Chunlizhengda Medical Instruments | 18.8x | 29.6% | HK$5.2b |
Price-To-Earnings vs Peers: 1858 is good value based on its Price-To-Earnings Ratio (18.8x) compared to the peer average (21.9x).
Price to Earnings Ratio vs Industry
How does 1858's PE Ratio compare vs other companies in the HK Medical Equipment Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
2393 Yestar Healthcare Holdings | 0.1x | n/a | US$20.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 1858 is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the Hong Kong Medical Equipment industry average (15.8x).
Price to Earnings Ratio vs Fair Ratio
What is 1858's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.8x |
| Fair PE Ratio | 17.2x |
Price-To-Earnings vs Fair Ratio: 1858 is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the estimated Fair Price-To-Earnings Ratio (17.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Hygeia Healthcare Holdings
HK$9.8b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$15.80
7D
-11.3%
1Y
-67.2%
Hygeia Healthcare Holdings
HK$9.8b
Offers oncology healthcare services in the People's Republic of China.
6078
HK$15.80
7D
-11.3%
1Y
-67.2%
Sinopharm Group
HK$62.7b
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
1099
HK$20.30
7D
1.2%
1Y
5.8%